Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.

@article{Stinson2017ManagingCN,
  title={Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.},
  author={Jordan Stinson and Kelvin K. W. Chan and Justin W. Lee and Ronald Chow and Paul M. Cheon and Angie Giotis and Mark Pasetka and Bo Angela Wan and Edward Chow and Carlo DeAngelis},
  journal={Annals of palliative medicine},
  year={2017},
  volume={6 Suppl 1},
  pages={
          S13-S20
        }
}
BACKGROUND The purpose was to retrospectively examine the anti-emetic regimens prescribed for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) for head and neck cancer patients receiving moderate- or high-emetogenic chemotherapy (MEC/HEC) along with concurrent radiation treatment at an outpatient ambulatory care center to determine the efficacy of anti-emetics prescribed. METHODS Consecutive patients with head and neck cancers who initiated cisplatin chemotherapy with concurrent… 
View on PubMed
doi.org
2 Citations

2 Citations

Citation Type

Citation Type

Matched pair analysis to evaluate the impact of hospitalization during radiation therapy as an early marker of survival in head and neck cancer patients.
Symptom Clusters in Head and Neck Cancer: A Systematic Review and Conceptual Model.

References

SHOWING 1-10 OF 28 REFERENCES
Concomitant weekly cisplatin and radiotherapy for head and neck cancer.
TLDR
This regimen appears to be a suitable alternative to three-weekly high-dose cisplatin with concomitant radiotherapy, because patients can be monitored more regularly for toxicity allowing the schedule to be altered if required.
Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial
TLDR
The results suggest that granisetron and dexamethasone combination therapy is useful in controlling acute and delayed nausea and vomiting induced by CDDP-containing chemotherapy for head and neck cancer.
Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
  • K. Ang, Jonathan Harris, +7 authors R. Weber
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
These data showed that it was feasible to combine AFX-C with cisplatin and the locoregional control and survival rates achieved compared favorably with AFx-C alone or other concurrent chemoradiation regimens tested by the Radiation Therapy Oncology Group.
Defining optimal control of chemotherapy-induced nausea and vomiting—based on patients’ experience
TLDR
Patients strongly favored a CINV end point that includes the absence of both nausea and vomiting, and thought the use of rescue medication for emesis control is inappropriate as it underestimates nausea.
Quality of Life of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving High-Dose Cisplatin Chemotherapy and Radiotherapy
TLDR
Healthcare providers need to be aware of the affected domains to provide improved QOL, well-being, and security to cancer patients who are receiving high-dose cisplatin and radiotherapy.
Concurrent chemoradiotherapy for T3–4 and N0–1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia
TLDR
The current results illustrate that the concurrent chemoradiotherapy regimen was feasible, but disease control remained insufficient, and further research is encouraged in order to improve clinical outcomes.
Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience
TLDR
Overall, the acute toxicity of this concurrent weekly chemo-radiation regimen though mildly increased did not mandate intensive supportive care and has moderate efficacy and acceptable acute toxicity with potential to be an optimal regimen in loco-regionally advanced squamous cell carcinoma of the head and neck, particularly in limited-resource settings.
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
TLDR
This trial failed to show any advantage of ICT-CCRT over CCRT alone in patients with unresectable LASCCHN, and there were no statistically significant differences for overall survival (OS).
Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy
TLDR
The present triple therapy can be recommended for supporting both carboplatin- based and cisplatin-based chemotherapy regimens.
Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey
TLDR
There is a perceptual gap between healthcare professionals and patients in terms of the incidence and impact of CINV/RINV, which may lead to sub-optimal prescription of anti-emetics and therefore management of CinV/ RINV.
...
1
2
3
...